HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRANSTHERA-B

10.310

-0.070-0.67%

Volume:4.54M

Turnover:46.60M

Market Cap:4.20B

PE:-11.63

High:10.440

Open:10.440

Low:10.120

Close:10.380

52wk High:679.500

52wk Low:9.010

Shares:407.00M

HK Float Shares:312.00M

Volume Ratio:0.52

T/O Rate:1.46%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.887

ROE:-62.88%

ROA:-32.06%

PB:8.64

PE(LYR):-11.63

PS:- -

Loading ...

Overview Company News Filings

TransThera Sciences names Feng Weibo independent director, replacing Zheng Zhelan

TransThera proposes bylaw amendments shifting supervisory powers to board audit committee

Transthera FY25 net loss widens 8% to RMB 296 million

TransThera Sciences: INED Zheng Zhelan to Exit, Feng Weibo Nominated as Successor; Non-Executive Director Yi Hua Resigns

Bulletin Express

TRANSTHERA-B Proposes Appointment of Feng Weibo as Independent Non-Executive Director

TransThera Sciences Widens Loss in 2025

MT Newswires Live

TRANSTHERA-B Reports 2025 Fiscal Year Results: Net Loss Widens to 296 Million Yuan

BRIEF-Transthera Sciences (Nanjing) FY Loss Attributable Rmb296 Million

Transthera Sciences (Nanjing) Inc - FY Loss Attributable RMB296 Mln

THOMSON REUTERS

TRANSTHERA-B (02617) Sets 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend

Bulletin Express

TransThera Sciences to hold board meeting on annual results and final dividend

Tencent Holdings Reports Annual Results with 16% Profit Growth and Final Dividend

TransThera Sciences Doses First Patient in Breast Cancer Drug Trial

MT Newswires Live

TRANSTHERA-B (02617) Administers First Dose in Phase II Trial of Tinengotinib Combined with Fulvestrant for Pretreated HR+/HER2- Breast Cancer

TransThera doses first patient in China Phase II trial of tinengotinib plus fulvestrant for HR+/HER2- metastatic breast cancer

Shares of Transthera Sciences Down 4%

THOMSON REUTERS

TransThera Sciences Included as Constituent of Hang Seng Index Series

MT Newswires Live

TRANSTHERA-B (02617) Selected as a Constituent of Hang Seng Index Series

Prospective Adjustments to Hong Kong Stock Connect in March: 44 Stocks Poised for Inclusion, Featuring Insilico (03696) and JD Industrials (07618)

TransThera Sciences (Nanjing), Inc. (02617) Announces Monthly Equity Return for February 2026

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/02617/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":10.31,"timestamp":1787299687057,"preClose":10.38,"halted":0,"volume":4543800,"delay":0,"changeRate":-0.006743737957610817,"floatShares":312000000,"shares":407000000,"eps":-0.8865534597111813,"marketStatus":"Not Yet Opened","change":-0.07,"latestTime":"08-21 16:08:07","open":10.44,"high":10.44,"low":10.12,"amount":46601191,"amplitude":0.030829,"askPrice":10.31,"askSize":5000,"bidPrice":10.3,"bidSize":10500,"shortable":3,"etf":0,"ttmEps":-0.886033192812456,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":10.38,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.5223118835745755,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":312000000,"roa":"-32.06%","roe":"-62.88%","lyrEps":-0.886553,"volumeRatio":0.5223118835745755,"shares":407000000,"dividePrice":0,"high":10.44,"amplitude":0.030829,"preClose":10.38,"low":10.12,"week52Low":9.01,"pbRate":"8.64","week52High":679.5,"institutionHeld":0,"latestPrice":10.31,"committee":0.354839,"eps":-0.8865534597111813,"divideRate":0,"volume":4543800,"delay":0,"ttmEps":-0.886033192812456,"open":10.44,"prevYearClose":114.9,"prevWeekClose":10.31,"prevMonthClose":9.95,"prevQuarterClose":11.55,"fiveDayClose":10.33,"twentyDayClose":10.19,"sixtyDayClose":38.7,"earningDate":1787673600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-08-21","current":-11.632445,"percent":0.95122,"low":-380.446233,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"high":-10.87103,"avg":-114.757849,"sd":96.187407,"marketCap":4205641106},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106}],"updateTime":1787493137953},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2624555183","title":"TransThera Sciences names Feng Weibo independent director, replacing Zheng Zhelan","url":"https://stock-news.laohu8.com/highlight/detail?id=2624555183","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624555183?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:41","pubTimestamp":1774993298,"startTime":"0","endTime":"0","summary":"TransThera Sciences  disclosed planned board reshuffle dated March 31, 2026, with independent director Zheng Zhelan set to step down once successor is elected at next annual general meeting.Board nominated Feng Weibo as independent non-executive director for a three-year term starting on shareholder approval.Feng is a retired Nanjing University education management researcher, previously serving in teaching and party secretary roles, currently independent director at Shenzhen-listed Nanjing Toua Hardware & Tools.Feng is slated to take over as chair of remuneration and appraisal committee, with seats on audit committee and nomination committee.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the origin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL3PNgJ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["301125","BK0259","02617","BK1615","BK1095","BK1161","09898"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624555374","title":"TransThera proposes bylaw amendments shifting supervisory powers to board audit committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2624555374","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624555374?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:31","pubTimestamp":1774992702,"startTime":"0","endTime":"0","summary":"TransThera Sciences proposed bylaw amendments to align governance documents with China’s revised Company Law.Plan dissolves supervisory committee, shifting its oversight duties to board audit committee.Shareholders will vote on amended articles of association via special resolution at upcoming annual general meeting.Revisions to rules for shareholders’ meetings, board procedures face ordinary-resolution votes at same meeting.Supervisory committee members will step down once amended articles take effect.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 31, 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLt4jdX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624558124","title":"Transthera FY25 net loss widens 8% to RMB 296 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624558124","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624558124?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:57","pubTimestamp":1774990665,"startTime":"0","endTime":"0","summary":"Transthera Sciences posted a net loss of RMB 296 million for fiscal 2025, with loss per share of RMB 0.76.Revenue was unchanged at no revenue, while loss before tax widened to RMB 296 million.Other income and gains fell 48.6% to RMB 9.2 million, due to lower interest income and reduced government grants.Tinengotinib’s new drug application for cholangiocarcinoma was accepted by China’s NMPA on Dec. 19, 2025, with a confirmatory Phase III trial ongoing in China and a registrational multi-regional Phase III trial underway overseas.Management expects Tinengotinib to secure NDA approval in China in 2026, while continuing Phase II combination trials in prostate cancer, breast cancer, and hepatocellular carcinoma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL4jb95x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107897077","title":"TransThera Sciences: INED Zheng Zhelan to Exit, Feng Weibo Nominated as Successor; Non-Executive Director Yi Hua Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=1107897077","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107897077?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:05","pubTimestamp":1774958722,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TransThera) announced a forthcoming reshuffle of its board on 31 March 2026, involving both independent and non-executive directors. Resignation of Independent...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163942223","title":"TRANSTHERA-B Proposes Appointment of Feng Weibo as Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1163942223","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163942223?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:58","pubTimestamp":1774958330,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that its board of directors received a resignation letter dated March 31, 2026, from the company's independent non-executive director, Ms. Zheng Zhelan. Due to personal...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623435585","title":"TransThera Sciences Widens Loss in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2623435585","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623435585?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:26","pubTimestamp":1774956404,"startTime":"0","endTime":"0","summary":"TransThera Sciences  widened its attributable loss in 2025 to 296 million yuan from 274.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.The clinical-stage biopharmaceutical firm's loss per share stood at 0.76 yuan in the fiscal year, compared with 0.72 yuan in the previous corresponding year.The firm did not record any revenue in both periods.Other income and gains fell 49% to 9.2 million yuan from 17.9 million yuan in the year-ago period, mainly due to a decline in interest income from bank deposits and wealth management products and lower government grants.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119552767","title":"TRANSTHERA-B Reports 2025 Fiscal Year Results: Net Loss Widens to 296 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1119552767","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119552767?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:50","pubTimestamp":1774954223,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced its annual results for the period ending December 31, 2025. Other income and gains fell by 48.6% year-on-year to 9.2 million yuan (Renminbi) for the 2025 fiscal year....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623289588","title":"BRIEF-Transthera Sciences (Nanjing) FY Loss Attributable Rmb296 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623289588","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623289588?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:45","pubTimestamp":1774953936,"startTime":"0","endTime":"0","summary":"BRIEF-Transthera Sciences (Nanjing) FY Loss Attributable Rmb296 MillionMarch 31 (Reuters) - TransThera Sciences (Nanjing) Inc 2617.HK:FY LOSS ATTRIBUTABLE RMB296 MILLIONFurther company coverage: 2617.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J0JD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623058819","title":"Transthera Sciences (Nanjing) Inc - FY Loss Attributable RMB296 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623058819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623058819?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:42","pubTimestamp":1774953731,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J0JD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181323580","title":"TRANSTHERA-B (02617) Sets 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1181323580","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181323580?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:22","pubTimestamp":1773915740,"startTime":"0","endTime":"0","summary":"On 19 March 2026, TransThera Sciences (Nanjing), Inc. (stock code: 02617, “TRANSTHERA-B”) announced that its board of directors will convene on 31 March 2026. The agenda includes: • Reviewing and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620246749","title":"TransThera Sciences to hold board meeting on annual results and final dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2620246749","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620246749?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:10","pubTimestamp":1773915047,"startTime":"0","endTime":"0","summary":"TransThera will hold a board meeting on 31 March 2026 to consider and approve its annual results announcement and to consider a final dividend.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 19, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL6dhhWb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169604080","title":"Tencent Holdings Reports Annual Results with 16% Profit Growth and Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1169604080","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169604080?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:25","pubTimestamp":1773883530,"startTime":"0","endTime":"0","summary":"Significant Developments: Saint Bella Group (02508) has entered into a strategic partnership with L Catterton to jointly develop a cross-sector high-end maternal-infant and lifestyle ecosystem....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0140636845.USD","LU1316542783.SGD","LU0509642566.USD","LU0737861772.HKD","SGXZ99366536.SGD","LU2237443978.SGD","LU0261947096.USD","LU1323998911.USD","LU2498475776.HKD","LU0886674414.USD","LU0051755006.USD","LU0052750758.USD","BK1610","LU0203345920.USD","LU1725190679.HKD","LU0359201612.USD","LU1211504680.USD","LU0359201885.HKD","LU1813983027.USD","LU1196710195.USD","BK1615","LU0873338254.USD","LU0289960550.SGD","LU0594300419.USD","IE00B8L5B284.USD","LU0396098781.USD","LU0149721374.USD","IE00BZ08YT58.USD","LU0791591158.USD","SG9999015952.SGD","LU1993786604.SGD","LU0049853897.USD","LU1048484197.HKD","IE00B97KM107.HKD","LU0210526637.USD","LU0214875030.USD","LU0084288322.USD","LU1064130708.USD","LU0588545730.USD","LU1226288253.USD","LU0823397285.USD","LU0572939691.SGD","LU1868837722.USD","LU0456842615.SGD","IE00BGV7N243.SGD","LU2279701549.SGD","LU0359202008.SGD","LU0173614495.USD","IE0008368742.USD","LU0348825331.USD","LU1242518857.USD","LU1282648689.USD","LU0228367735.SGD","BK1618","LU0672654166.SGD","LU1951186391.HKD","LU2097828557.USD","SG9999014674.SGD","LU1794554557.SGD","IE0003795394.USD","LU1303224171.USD","SGXZ81514606.USD","GB00BDT5M118.USD","LU0345776255.USD","LU2362540622.SGD","SG9999014898.SGD","IE00B5MMRT66.SGD","BK1517","SG9999018865.SGD","LU1188198961.HKD","LU0516422952.EUR","IE00B0169N27.USD","SGXZ31699556.SGD","LU0072462343.USD","LU0049112450.USD","LU1328277881.USD","LU1226288097.SGD","LU1282649067.USD","BK1591","LU0577902538.SGD","LU0823413587.USD","LU2152927971.USD","SG9999018857.SGD","LU1642822792.SGD","LU0149534421.HKD","LU1282651121.HKD","LU1831875114.USD","LU1868838027.USD","VIG","LU0047713382.USD","BK1209","LU0648948544.HKD","LU2097828631.EUR","LU1719994722.HKD","IE00B0169L03.USD","LU0862451837.USD","LU1102505929.USD","IE00BZ08YR35.GBP","LU1814569148.SGD","LU0499858438.USD","LU0588545490.SGD","LU1974910355.USD","LU0572944931.SGD","LU2237443622.USD","LU1328615791.USD","LU1720050803.USD","LU0070217475.USD","LU2097828805.USD","LU1675838814.USD","LU1064131003.USD","LU0516422366.SGD","LU0029874905.USD","LU0819121731.USD","LU2462611646.USD","LU2449936058.SGD","SG9999001689.USD","LU1196710864.SGD","LU0871576103.HKD","LU1102505762.USD","LU0117844026.USD","IE00BQXX3C00.GBP","LU0244354667.USD","LU1981816686.USD","LU2097828714.EUR","LU0181495838.USD","HK0000352291.HKD","LU0251144936.SGD","BK1161","LU2257852520.SGD","BK1608","LU0516423091.SGD","LU0228659784.USD","LU0414403682.SGD","SG9999003461.SGD","LU0329678170.USD","IE00BQXX3F31.USD","LU0043850808.USD","LU1807302812.USD","IE00BZ08YS42.EUR","LU0828237940.HKD","IE0032431581.USD","LU0499858602.USD","SG9999017495.SGD","LU0107464264.USD","LU0211977185.USD","LU0878004406.USD","BK1589","SGXZ51526630.SGD","LU2125910849.SGD","LU2476274308.USD","LU0229945570.USD","SG9999001226.SGD","BK1502","LU0175139822.USD","SG9999007991.SGD","HK0000320223.HKD","LU0823040885.USD","LU0608807433.USD","LU0011963245.USD","LU0345769128.USD","LU1051769294.HKD","LU0072913022.USD","LU0128522744.USD","LU1023057109.AUD","LU0345769631.USD","02172","LU0210533765.USD","LU0463099449.HKD","LU2087589342.USD","BK1526","LU0117841782.USD","LU0315178854.USD","LU0345775950.USD","LU1105468828.SGD","LU2778985437.USD","IE00B29SXG58.USD","LU2039709279.SGD","LU2242644610.SGD","LU0456827905.SGD","BK1095","LU0164872284.USD","LU3063872942.SGD","SG9999001069.SGD","LU1224444064.USD","LU1008478684.HKD","LU1044874839.SGD","LU1282651048.USD","LU0329678337.USD","LU1048588211.SGD","LU0797268264.HKD","LU0865486749.SGD","LU0543330566.HKD","LU0231483743.USD","LU1880383440.USD","IE00B543WZ88.USD","LU0164865239.USD","SG9999001846.SGD","LU0269904917.USD","LU0828238088.HKD","IE0031814852.USD","LU1629966141.USD","IE0008369823.USD","LU0650527681.SGD","LU2177674079.SGD","LU2476274720.SGD","LU1568876335.HKD","LU0096374516.USD","LU0786609619.USD","IE00B031HY20.USD","LU1868837565.USD","LU1224709979.USD","LU0106259558.USD","LU1718418525.SGD","LU0516423174.USD","LU0029875118.USD","LU0348783233.USD","LU0642271901.SGD","LU1481107354.HKD","LU0417516738.SGD","LU0169518387.USD","LU0823426480.USD","IE00B067MR52.USD","LU0127658192.USD","IE00B8HQ1Z84.USD","LU2237443382.USD","LU0862451753.SGD","LU1152091168.USD","LU0348735423.USD","LU2399975544.HKD","LU1770034418.SGD","LU0417516902.SGD","SG9999006514.SGD","LU1051768304.USD","LU0683595622.HKD","LU0449515922.USD","LU0370786039.SGD","IE0003895053.USD","LU1196710351.USD","LU0163747925.USD","LU1804176565.USD","LU0651947912.USD","LU1734074674.USD","LU1226288170.HKD","LU0633140560.USD","LU1655091459.SGD","IE00BF5LJ272.USD","LU0326948709.USD","LU0348723411.USD","LU0516422440.USD","LU0588546209.SGD","LU0541502299.USD","LU0456846285.SGD","LU0823413660.USD","LU2237443549.SGD","IE0001KFT4U8.USD","LU2008162690.USD","BK1516","LU2247934214.USD","LU0819123356.HKD","LU0823038988.USD","LU0577902298.EUR","LU0738912210.USD","SG9999001051.SGD","HTCD.SI","LU0882747503.HKD","LU0039217434.USD","LU0700851271.USD","LU0821914370.USD","LU0192582467.USD","LU0594300179.USD","SG9999014914.USD","LU0384037296.USD","LU0441854154.USD","SG9999002828.SGD","LU0235996351.USD","LU0823041008.USD","LU0918141887.USD","SG9999000327.SGD","LU2293587155.HKD","LU0188438112.USD","LU0543330483.HKD","LU0823397103.USD","LU0878005551.USD","LU0067412154.USD","LU0561508036.HKD","LU0633140727.USD","LU1366334578.USD","LU0605514214.HKD","LU1044875133.USD","LU2251237488.HKD","LU0061477393.USD","LU0048388663.USD","LU0501845795.SGD","LU1439103000.SGD","LU0488056044.USD","LU0320764599.SGD","LU2023250504.SGD","LU0856984785.SGD","SG9999015978.USD","IE00B031J352.USD","LU0080751232.USD","HK0001040168.HKD","LU0164880469.USD","LU0634319403.HKD","LU1808992512.USD","LU1226287792.SGD","LU0211331839.USD","LU0254981946.USD","LU0985320562.USD","LU1235295612.USD","IE0008368411.USD","LU0293314216.USD","LU1515016050.SGD","SG9999000459.SGD","LU0469268626.HKD","LU0128522157.USD","LU0831103253.SGD","LU2051468812.USD","LU2125910500.SGD","LU2148510915.USD","LU0577902371.SGD","LU1366334651.USD","LU0348816934.USD","LU0314109678.HKD","LU0348827113.USD","LU0593848301.USD","LU2317271919.USD","LU1242518931.SGD","LU0880133367.SGD","HK0000306701.USD","LU0106252389.USD","LU0348814723.USD","LU0327786744.USD","LU0287142896.SGD","LU0607220059.USD","LU2362541273.HKD","LU0196878994.USD","02617","LU0608807946.USD","LU0531971595.HKD","HK0000320264.USD","LU1504937902.USD","LU0328353924.USD","LU0502904849.HKD","LU1226287875.USD","LU0106959298.USD","LU0898667661.SGD","SG9999006597.SGD","IE00B031HW06.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU0449509016.USD","LU2265009873.SGD","LU0737861699.HKD","VXUS","SG9999001093.SGD","LU1770036033.HKD","LU0708995153.HKD","LU0455707207.USD","HK0000306685.HKD","LU0828237510.HKD","LU0572940350.SGD","LU0348788117.USD","LU1733274390.USD","LU0577902454.USD","LU2251237306.USD","LU1769817179.HKD","LU0651946864.USD","LU0972618739.USD","SG9999002562.SGD","LU0890818403.SGD","LU1044876610.USD","02508","LU1568876251.USD","LU0823039010.USD","LU0261950983.USD","BK4585","BK1586","SG9999014906.USD","LU0048580855.USD","LU2237443895.HKD","SG9999002463.SGD","LU1048596156.SGD","SG9999000418.SGD","LU0588545904.SGD","LU0348783662.USD","SG9999013353.USD","BK4588","LU0054237671.USD","LU0348784397.USD","LU1691799644.USD","LU1439102457.SGD","IE00B3M56506.USD","LU0708995583.HKD","IE0003851619.USD","LU1733274473.HKD","LU2097828474.EUR","LU0132412106.USD","LU1961090484.USD","SG9999014880.SGD","LU1880383366.USD","LU1956131251.USD","LU0868486357.SGD","LU0048597586.USD","LU0054450605.USD","HK0000914686.HKD","LU2106854487.HKD","LU1152091754.HKD","LU0791590937.USD","LU0320764755.SGD","LU0210527791.USD","LU0259732245.USD","BK1609","LU1226287529.USD","LU1282649141.HKD","LU1688375341.USD","LU2045819591.USD","LU0417516571.SGD","HK0000914660.USD","BK1521","LU0348805143.USD","LU0541501648.USD","LU0611395673.USD","LU0979878070.USD","HK0000352382.USD","IE0032834883.USD","LU1960683339.HKD","IE0009570106.USD","BK1100","LU1785774172.SGD","LU0431992006.USD","LU1046422090.SGD","LU2362541513.USD","TCHmain","BK1531","LU0307460666.USD","LU0589944569.HKD","SG9999004220.SGD","SGXZ90724238.SGD","SG9999001903.USD","SG9999015945.SGD","LU0823426308.USD","SG9999015986.USD","LU1883866441.USD","LU2237443465.HKD","LU0675040207.SGD","LU0264606111.USD","LU0531970944.HKD","IE00B0JY6N72.USD","LU0918141705.HKD","LU0320764243.SGD","LU1769817096.USD","LU0143863784.USD","LU2133065610.SGD","IE00BQXX3D17.EUR","LU0577902611.USD","LU0143863198.USD","LU1810669033.SGD","00700","LU0326950275.SGD","LU2226246903.HKD","LU0784639295.USD","IE0034224299.USD","LU0165289439.USD","LU1917777945.USD","LU1282649810.SGD","LU1251922891.USD","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620230106","title":"TransThera Sciences Doses First Patient in Breast Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2620230106","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620230106?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:28","pubTimestamp":1773833334,"startTime":"0","endTime":"0","summary":"TransThera Sciences  dosed the first patient in a phase II clinical trial of Tinengotinib in combination with Fulvestrant for the treatment of breast cancer, according to a Wednesday Hong Kong bourse filing.The study being conducted in China aims to evaluate the safety, efficacy, and pharmacokinetics of the drug in the relevant combination.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131367321","title":"TRANSTHERA-B (02617) Administers First Dose in Phase II Trial of Tinengotinib Combined with Fulvestrant for Pretreated HR+/HER2- Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1131367321","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131367321?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:58","pubTimestamp":1773831506,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that the first patient has been dosed in a Phase II clinical study of its core product Tinengotinib (TT-00420) in combination with fulvestrant. The trial targets...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4225","02617","HR","BK4203"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232765","title":"TransThera doses first patient in China Phase II trial of tinengotinib plus fulvestrant for HR+/HER2- metastatic breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232765","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232765?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:52","pubTimestamp":1773831137,"startTime":"0","endTime":"0","summary":"TransThera doses first patient in China Phase II trial of tinengotinib plus fulvestrant for HR+/HER2- metastatic breast cancer. TransThera said the first patient has been dosed in a China-based, open-label, multicenter phase II trial of tinengotinib  in combination with fulvestrant for previously treated HR+/HER2- relapsed or metastatic breast cancer. The study will evaluate safety, efficacy, and pharmacokinetics in patients who previously received endocrine therapy and a CDK4/6 inhibitor. The announcement did not report clinical results, and no timing for future data presentation was provided.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via II","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL2DsMk5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618197911","title":"Shares of Transthera Sciences  Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618197911","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618197911?lang=en_us&edition=fundamental","pubTime":"2026-03-11 15:51","pubTimestamp":1773215485,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL4N3ZZ0KK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618623289","title":"TransThera Sciences Included as Constituent of Hang Seng Index Series","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623289","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618623289?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:53","pubTimestamp":1773057226,"startTime":"0","endTime":"0","summary":"TransThera Sciences (HKG:2617) will be included as a constituent of the Hang Seng Index Series effective Monday, March 9, according to a same-day Hong Kong bourse filing.The clinical-stage biopharmaceutical firm has been deleted from the Hang Seng Composite SmallCap Index effective the same day.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145719914","title":"TRANSTHERA-B (02617) Selected as a Constituent of Hang Seng Index Series","url":"https://stock-news.laohu8.com/highlight/detail?id=1145719914","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145719914?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:47","pubTimestamp":1773053266,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that, according to the quarterly review results of the Hang Seng Index Series released by Hang Seng Indexes Company Limited on February 13, 2026, the company has been...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","513600","02833","HHImain","MCHmain","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179855228","title":"Prospective Adjustments to Hong Kong Stock Connect in March: 44 Stocks Poised for Inclusion, Featuring Insilico (03696) and JD Industrials (07618)","url":"https://stock-news.laohu8.com/highlight/detail?id=1179855228","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179855228?lang=en_us&edition=fundamental","pubTime":"2026-03-06 14:32","pubTimestamp":1772778725,"startTime":"0","endTime":"0","summary":"According to the quarterly review results announced by Hang Seng Indexes Company on February 13, the adjustments will officially take effect starting March 9 (next Monday). Following the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","BK1231","02609","BK1160","03696","BKEAY","03660","BK1175","QFIN","02788","02617","01384","00659","02007","BK4588","NWSGY","BK1141","02698","SG9999003461.SGD","07618","BK1230","02656","03887","BK1572","CTRYY","BK1170","BK4585","BK1117","00023","BK1207","BK1601","BK1124","00863"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150834291","title":"TransThera Sciences (Nanjing), Inc. (02617) Announces Monthly Equity Return for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1150834291","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150834291?lang=en_us&edition=fundamental","pubTime":"2026-03-03 18:41","pubTimestamp":1772534496,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (02617) released its monthly return on movements in securities for the period ending 28 February 2026. According to the announcement, the authorized share capital...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":7,"totalSize":140,"code":"91000000","status":"200"}]}}